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1. Introduction
Interstitial lung diseases are rare diffuse lung disease characterized by a specific 
clinical picture and radiological (imaging) and pathohistological findings. It is 
considered that these diseases represent about 15% of all respiratory diseases [1].
Diffuse changes of the lung parenchyma in each type of these diseases are 
characterized by various morphological patterns which are reflected by a different 
imaging finding and a specific clinical picture [2–4]. The clinical picture at an early 
stage of the disease is not specific, and it is hard to suspect interstitial lung dis-
ease. Symptoms of interstitial lung disease are dry cough, short breath, fever, and 
fatigue. A specific high resolution - computed tomographyn (HR-CT)  finding indi-
cates an interstitial lung disease which is proven by biopsy. Transbronchial biopsy 
primarily excludes specific granulomatous lung diseases, primary malignancy and 
metastatic as well as eosinophilic pneumonia, alveolar proteinosis, and pulmonary 
histiocytosis. If a bioptized lung sample has nonspecific morphological pattern, 
it is necessary to perform an open lung biopsy or video-assisted thoracoscopic 
surgery (VATS). Open lung biopsy procedure requires a multidisciplinary approach 
that includes a chest surgeon. An agreement on taking large number of lung tissue 
samples characterized by change evolution increases the efficiency and accuracy of 
the diagnosis [5].
Integrated clinical and radiological data help the pathologist to establish an 
accurate diagnosis of the type of interstitial lung disease. Besides pulmonologist, 
radiologist, and pathologist, microbiologist and immunologist also participate in 
diagnostic procedure [2–4].
2.  Pathohistological diagnosis of interstitial lung disease in open lung 
biopsy
It is necessary to take the entire surgical material for processing and microscopic 
analysis. Before all, it is necessary to completely instill 10% buffered formalin 
into the lung parenchyma with a needle for injection but in a moderate amount, in 
order to not provoke artifacts in the lung parenchyma. In such a manner, alveolar 
spaces are as if they were in the air-inspiration phase, and also damages on the lung 
parenchyma caused by a forceps during biopsy performed by a surgeon are avoided. 
After fixation that lasts 24 h, the entire material is sampled into thin sections which 
are fixed in the buffered formalin, alcohol, and xylol. After that, they are embedded 
into paraffin and then cut and stained with a classical hematoxylin-eosin staining.
The pathologist at first performs microscopic examination on a low-powered-
field microscope in order to see the distribution of changes, that is, whether they are 
confluent or not. Then he observes localization of changes and their peribronchial or 
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perivascular presence or connective subpleural, interlobular, or interalveolar septa. On 
highermicrosopic microscopic field enlargements, the cellularity of changes is noted, 
as well as the type of cells that contain changes and then the presence and degree of 
fibrosis. By connective tissue staining, it is desirable to confirm the degree of fibrosis 
and with other methods to determine type of cells and presence of microorganisms. 
Immunohistochemical technique can detect the type of cells in the analyzed changes [5].
On the basis of the overall finding, descriptive diagnosis that correlates with 
the disease entity is made. Diagnosis must correlate with the clinical and imaging 
picture by the type of change. For this purpose, current classification of interstitial 
lung diseases is used [5].
The first used classification of interstitial diseases in different subtypes is 
according to Liebow and Carrington [6]. By consensus of the American Thoracic 
Society and European Respiratory Society (ATS/ERS), current classification of 
interstitial lung diseases is determined. This classification defines different clinical-
pathological entities according to clinical, radiological, and histological criteria. By 
using this classification, it is possible to predict the course of the disease, treatment, 
and outcome. Therapy and monitoring of the disease course require consultative 
decisions. The medical advisory board consists of experienced pulmonologists, 
radiologists, and pulmonary pathologists. If the course of the disease is not satisfac-
tory even with applied therapy, treatment may be evaluated, and in exceptional 
circumstances, archived tissue samples can be reexamined and diagnosis can be 
changed [1]. In addition to the therapy, in order to improve lung function which is 
tested by various functional tests, physical therapy is also desirable.
The ATS/ERS classification of these diffuse lung diseases divides them into those 
of known and those of unknown etiologies [1]. According to ATS/ERS classifica-
tion, morphological image in the lung parenchyma should correspond to clinical-
pathological diagnosis (in this part of the text, insert Table 1 from the bottom of 
the text).
Diffuse diseases of known etiology, such as connective tissue diseases or diseases 
caused by taking some drugs, are less common. Allergic alveolitis or hypersen-
sitivity pneumonitis is a specific entity of generally known etiology. Diseases of 
unknown etiology, that is, idiopathic diseases such as idiopathic lung disease, non-
specific interstitial lung disease, desquamative interstitial pneumonia, respiratory 
bronchiolitis, organized pneumonia, acute interstitial pneumonia, and lymphoid 
interstitial pneumonia, are more frequent. This group of diseases includes granulo-
matosis of which the most common is sarcoidosis characterized by the presence of 
epithelial, non-necrotizing granulomas [1].
Histological pattern Clinicopathological diagnosis
Usual interstitial pneumonia (UIP) Idiopathic pulmonary fibrosis (IPF)/cryptogenic fibrosing 
alveolitis (CFA)
Nonspecific interstitial pneumonia (NSIP) Nonspecific pneumonia
Organizing pneumonia Cryptogenic organizing pneumonia
Diffuse alveolar damage (DAD) Acute interstitial pneumonia
Desquamative interstitial pneumonia (DIP) Desquamative interstitial pneumonia
Respiratory bronchiolitis Respiratory bronchiolitis-interstitial lung disease 
(RB-ILD)
Lymphocytic interstitial pneumonia (LIP) Lymphocytic interstitial pneumonia
Table 1. 
Morphological image which corresponds to a certain clinical-pathological diagnosis according to the ATS/ERS 
classification [1].
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By using the said formulations, uniformity of the findings is achieved and 
therapy is specified. If good treatment results fail, it comes to a stage known as 
“end-stage lung disease.” In such a case, lung transplantation is proposed which 
lately requires a special chapter in each textbook about these diseases. Selection of 
the transplantation type (single, bilateral, or heart-lungs) depends on the type of 
interstitial lung disease and other factors. The success of transplantation depends 
on the type of organism reaction on the presence of the transplanted lung or the 
type of rejection which can be subacute, acute, and chronic. Changes in rejec-
tion reactions are localized around the blood vessels of the lungs or bronchi. The 
intensity of rejection reaction depends on the extent of the changes spreading in 
the pulmonary interstitium and the type of inflammatory infiltrate. Prevention and 
treatment of rejection are regulated by immunosuppressive drugs. Therefore, it is 
necessary to control the presence of microorganisms in the transplanted lung by 
microbiological tests and transbronchial biopsy [7–9].
However, the future of the treatment of interstitial lung diseases depends on the 
molecular changes in the cells found in the lesions. miRNAs profiling in lung tissue 
in various interstitial lung diseases in a variety of cells that contain lung lesions: 
endothelium, alveolar epithelium, inflammatory cells, fibroblast and myofibroblast. 
This profiling can determine the type of therapy and their outcome or success.
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